non-alcoholic fatty liver disease
Conditions
Interventions
None listed
Sponsors
Department of Gastroenterology and Hepatology, Yokohama City University Hospital
Drug Discovery Department, Chemistry Research Group, EA Pharma Co., Ltd
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who have been diagnosed with NAFLD by histological or imaging studies within 6 months. Patients who have not been diagnosed with NAFLD by imaging studies such as ultrasonography and MRI within 6 months.
Exclusion criteria
Exclusion criteria: Patients who have used antimicrobial agents within one month of blood and stool specimen collection Patients who have been diagnosed with infectious hepatitis (hepatitis B or C, HIV infection), autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, hemochromatosis, alpha1-antitrypsin deficiency, Wilson's disease, drug-induced hepatitis, alcoholic hepatitis, or are known to consume excessive amounts of alcohol Patients who are unable to collect specimens due to defecation disorder. Patients who do not wish their medical information to be used for research purposes. Patients who are judged by the physician to be unsuitable for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of serum and fecal amino acid concentrations between NAFLD and non-NAFLD patients | — |
Countries
Japan
Contacts
Public ContactMichihiro Iwaki
Yokohama City University Hospital Department of Gastroenterology and Hepatology
Outcome results
None listed